P53 as a marker of prognosis in African-american women with breast cancer

Annals of Surgical Oncology

Volumn 17, Issue 5, 2010, Pages 1398-1405

  Dookeran, Keith A ^a   Dignam, James J ^b   Ferrer, Karen ^c   Sekosan, Marin ^c   McCaskill Stevens, Worta ^d   Gehlert, Sarah ^b  

^a Cancer Foundation for Minority and Underserved Populations   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Jr Hospital of Cook County   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROGNOSIS; SOCIAL STATUS;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOCIOECONOMIC FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952095168     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0889-3     Document Type: Article

References (39)

1. A Jemal R Siegel E Ward, et al. 2008 Cancer Statistics, 2008 CA Cancer J Clin 58 2 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. LA Carey CM Perou CA Livasy, et al. 2006 Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 295 21 2492 2502 10.1001/jama.295.21.2492 1:CAS:528:DC%2BD28XlsV2rtLw%3D 16757721 (Pubitemid 43854964)
3. JW Eley HA Hill VW Chen, et al. 1994 Racial differences in survival from breast cancer Results of the National Cancer Institute Black/White Cancer Survival Study JAMA 272 12 947 954 10.1001/jama.272.12.947 1:STN:280: DyaK2czms1Sguw%3D%3D 8084062 (Pubitemid 24288549)
4. Field TS, Buist DS, Doubeni C, et al. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr. 2005;35:88-95.
5. J Peppercorn CM Perou LA Carey 2008 Molecular subtypes in breast cancer evaluation and management: Divide and conquer Cancer Invest 26 1 1 10 10.1080/07357900701784238 1:CAS:528:DC%2BD1cXisFOluw%3D%3D 18181038
6. Dookeran K, Gao X, Wang Y, et al. Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer. AACR Meeting Abstracts. April 14, 2007 2007;2007(1-Annual-Meeting):2510.
7. MCU Cheang D Voduc C Bajdik, et al. 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 5 1368 10.1158/1078-0432.CCR-07-1658 1:CAS:528: DC%2BD1cXislSrs7o%3D 18316557 (Pubitemid 351413917)
8. KR Bauer M Brown RD Cress CA Parise V Caggiano 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry Cancer 109 9 1721 1728 10.1002/cncr.22618 17387718 (Pubitemid 46668532)
9. DeNavas-Walt C, Proctor BD, Lee CH. Income, Poverty, and Health Insurance Coverage in the United States: 2005. U.S. Census Bureau, Current Population Reports, U.S. Government Printing Office, Washington, DC. 2006:60-231.
10. KA Dookeran K Ferrer M Sekosan, et al. 2006 p53 expression in breast cancer is more likely to predict survival in African-American than Hispanic or white women J Clin Oncol (Meeting Abstracts) 24 18-suppl 10001
11. H Blaszyk CB Vaughn A Hartmann, et al. 1994 Novel pattern of p53 gene mutations in an American black cohort with high mortality from breast cancer Lancet 343 8907 1195 1197 10.1016/S0140-6736(94)92403-1 1:STN:280: DyaK2c3jtFyltg%3D%3D 7909871 (Pubitemid 24147556)
12. YH Shiao VW Chen WD Scheer XC Wu P Correa 1995 Racial disparity in the association of p53 gene alterations with breast cancer survival Cancer Res 55 7 1485 1490 1:CAS:528:DyaK2MXkslWisbo%3D 7882357
13. YH Shiao VW Chen XC Wu, et al. 1996 Racial comparison of p53 alterations in breast cancer: Difference in prognostic value In Vivo 10 2 169 173 1:CAS:528:DyaK28XjvFygsr8%3D 8744796 (Pubitemid 26001179)
14. AM Oliveira JA Fletcher JS Ross 2005 Tumor Suppressor Genes in Breast Cancer: The Gatekeepers and the Caretakers Pathol Patterns Rev 124 1 16 28 10.1309/5XW3L8LU445QWGQR
15. RM Elledge GM Clark GC Chamness CK Osborne 1994 Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States J Natl Cancer Inst 86 9 705 712 10.1093/jnci/86.9.705 1:STN:280:DyaK2c3htVGmsA%3D%3D 7908990
16. BA Jones SV Kasl CL Howe, et al. 2004 African-American/White differences in breast carcinoma: P53 alterations and other tumor characteristics Cancer 101 6 1293 1301 10.1002/cncr.20500 15368321 (Pubitemid 39180384)
17. PL Porter MJ Lund MG Lin, et al. 2004 Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma Cancer 100 12 2533 2542 10.1002/cncr.20279 15197793 (Pubitemid 38715756)
18. US-Census-Bureau. American Fact Finder. http://factfinder.census.gov/ home/saff/main.html?-lang=en. Accessed 11/4/09.
19. Commission on Cancer of the American College of Surgeons. Cancer Program Standards 2004. http://www.facs.org/cancer/coc/cocprogramstandards.pdf. Accessed 9/25/08.
20. CW Elston IO Ellis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up Histopathology 19 403 10 10.1111/j.1365-2559. 1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D 1757079
21. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. IARC; 2003.
22. Fleming ID, Cooper JS, Hensen DE (editors). AJCC cancer staging manual, 5 ed. Philadelphia: Lippincott-Raven; 1998.
23. Greene FL Page DL, Fleming ID (editors). AJCC cancer staging manual, 6 ed. New York: Springer Verlag; 2002.
24. TO Nielsen FD Hsu K Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 16 5367 5374 10.1158/1078-0432.CCR-04-0220 1:CAS:528: DC%2BD2cXmvFSlt7k%3D 15328174 (Pubitemid 39100473)
25. DC Allred JM Harvey M Berardo GM Clark 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis Mod Pathol 11 2 155 168 1:STN:280:DyaK1c7mtlaitg%3D%3D 9504686 (Pubitemid 28144151)
26. Klein JP, Moeschberger ML. Survival analysis: Techniques for censored and truncated data. New York: Springer Verlag; 2003.
27. RW Makuch 1982 Adjusted survival curve estimation using covariates J Chron Dis 35 6 437 444 10.1016/0021-9681(82)90058-3 1:STN:280: DyaL387ptVajtA%3D%3D 7042727 (Pubitemid 12117326)
28. MA Troester JI Herschkowitz DS Oh, et al. 2006 Gene expression patterns associated with p 53 status in breast cancer BMC Cancer 6 1 276 10.1186/1471-2407-6-276 17150101 (Pubitemid 46178680)
29. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci 98 19 10869 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D 11553815 (Pubitemid 32878711)
30. BP Schneider EP Winer WD Foulkes, et al. 2008 Triple-negative breast cancer: risk factors to potential targets Clin Cancer Res 14 24 8010 8018 10.1158/1078-0432.CCR-08-1208 1:CAS:528:DC%2BD1cXhsV2it73F 19088017
31. Levine AJ, Hu W, Feng Z. Tumor suppressor genes. In: Mendelsohn J, Howley PM, Israel MA, Gray JW, Thompson CB, editors. The molecular basis of cancer, 3rd ed. Philadelphia: Saunders Elsevier; 2008:31-8.
32. Dookeran KA, Gao X, Wang Y, Lukaszczyk B, DeLaTorre R, Roman G, Ferrer K, Sekosan M, McCaskill-Stevens W, Zaren HA. p53 gene mutations in African-American women with breast cancer. Breast Cancer Res Treat. 2006;100(Supplement 1):(December 2006):S145.
33. AD Thor DH Moore SM Edgerton, et al. 1992 Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers JNCI 84 11 845 855 10.1093/jnci/84.11.845 1:CAS:528:DyaK38XlsVyhsLc%3D 1317462
34. DC Allred GM Clark R Elledge, et al. 1993 Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer JNCI 85 3 200 206 10.1093/jnci/85.3.200 1:STN:280:DyaK3s7ktVWksQ%3D%3D 8423624 (Pubitemid 23046895)
35. J Bergh T Norberg S Sjogren A Lindgren L Holmberg J Coplete 1995 Sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy Nat Med. 1 1029 1034 10.1038/nm1095-1029 1:CAS:528:DyaK2MXosVGgu70%3D 7489358
36. LN Harris G Broadwater NU Lin, et al. 2006 Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 Breast Cancer Res. 8 R66 10.1186/bcr1622 17129383 (Pubitemid 350201714)
37. D Kandioler-Eckersberger C Ludwig M Rudas, et al. 2000 TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients Clin Cancer Res 6 1 50 56 1:CAS:528:DC%2BD3cXhtVequ78%3D 10656431 (Pubitemid 30064975)
38. Baker L, Quinan PR, Patten N, Ashfield A, Bourdon J, Purdie C, Jordan L, Dewar J, Wu L, Thompson AM. Association between p53 mutation, deprivation and prognosis in primary breast cancer. http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview=abst-detail-view&confID= 58&abstractID=40333. Accessed 11/2/08.
39. L Harris H Fritsche R Mennel, et al. 2007 American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 33 5287 5312 10.1200/JCO.2007.14.2364 1:CAS:528:DC%2BD2sXhsVKnsbzK 17954709 (Pubitemid 350232263)